Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Status:
Not yet recruiting
Trial end date:
2026-10-27
Target enrollment:
Participant gender:
Summary
To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in
participants with PSMA-expressing metastatic castrate resistant prostate cancer.